NFE2L2 and breast cancer: Expected associations of cancer type with somatic pathway alteration were observed, including MYC amplification in breast cancer; Wnt pathway alterations via APC mutation in colorectal cancer; NRF2 pathway alteration in squamous lung cancer; KRAS mutations in colorectal, lung adenocarcinoma, and pancreatic cancers; TP53 mutations in ovarian, lung squamous, and head and neck cancers; and mTOR pathway alterations via VHL mutation in renal cancer.